RORZE CORPORATION

The RORZE Group’s core business is the design, manufacture and sale of semiconductor- and FPD-related equipment, and it also operates a life sciences business. For the interim consolidated accounting period from 1 September 2025 to 31 August 2026, revenue was ¥79,733 million, up 21.5% year on year, ordinary income was ¥24,538 million, up 68.4% year on year, and interim net income attributable to owners of the parent was ¥15,839 million, up 45.7% year on year. By segment, revenue from the semiconductor- and FPD-related equipment business was ¥79,357 million, up 21.6% year on year, and segment profit was ¥23,969 million, up 43.0% year on year. The life sciences business recorded revenue of ¥376 million, up 2.8% year on year, but posted a segment loss of ¥147 million, compared with a loss of ¥119 million in the same period of the previous year. At the end of the interim period, assets were ¥218,038 million, liabilities were ¥62,051 million and net assets were ¥155,987 million. Cash and cash equivalents at the end of the interim period totaled ¥86,328 million. Cash flow from operating activities was ¥8,730 million, cash flow from investing activities was negative ¥2,006 million and cash flow from financing activities was ¥4,585 million. Total research and development expenses were ¥931 million. There were no decisions on or executions of material contracts or similar agreements. Matters concerning the future during the interim consolidated accounting period are based on judgments made as of the present time.